Follow the Money: The Outlook for Outsourced Spending on Early Development Services
Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs.
Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in…
Bio/Pharma CapEx Trends 2016
Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.
Having spent over $150 billion for new plant and equipment in the past 5 years, it’s clear that global bio/pharma companies would rather…
Contract Manufacturing Market Opportunities for Antibody Drug Conjugates
This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.
The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company…